An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs M 4344 (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono Research & Development Institute; Vertex Pharmaceuticals
- 25 May 2018 Planned End Date changed from 27 May 2019 to 27 Sep 2019.
- 25 May 2018 Planned primary completion date changed from 27 May 2019 to 23 Sep 2019.
- 25 May 2018 Part A2 consisting "M4344 BID or once daily" is added to the study.